Campos Denise Johnsson, Biagini Gleyne Lopes Kujew, Funke Vaneuza Araujo Moreira, Bonfim Carmem Maria Sales, Boguszewski César Luiz, Borba Victória Zeghbi Cochenski
Universidade Federal do Paraná, Curitiba, PR, Brazil, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brazil.
Rev Bras Hematol Hemoter. 2014 Mar;36(2):126-31. doi: 10.5581/1516-8484.20140029.
Sub-optimal levels of vitamin D have been found to be highly prevalent in all age groups, with epidemiologic studies demonstrating a link between vitamin D deficiency and disease susceptibility, such as infection and cancer, and mortality rates. In adult transplant patients, it has been suggested that the immunomodulatory properties of vitamin D may have an important role in the prevention and treatment of graft-versus-host disease.
The objective of this study was to assess serum 25-hydroxyvitamin D levels of children and adolescents submitted to allogeneic hematopoietic stem cell transplantation.
Serum 25-hydroxyvitamin D levels of 66 patients, aged 4-20 years, were assessed at three stages: before hospitalization for hematopoietic stem cell transplantation and at 30 and 180 days after hematopoietic stem cell transplantation. The control group consisted of 25 healthy children.
At the pre-hematopoietic stem cell transplantation stage, patients had lower levels of 25-hydroxyvitamin D compared to controls (25.7 ± 12.3 ng/mL vs. 31.9 ± 9.9 ng/mL; p-value = 0.01), and a higher prevalence of 25-hydroxyvitamin D deficiency (32% vs. 8%; p-value = 0.01). Prevalence increased significantly after hematopoietic stem cell transplantation (p-value = 0.01) with half of the patients having vitamin D deficiency at 180 days after transplantation. At this stage, mean serum 25-hydroxyvitamin D levels were 20.9 ± 10.9 ng/mL, a significant decline in relation to baseline (p-value = 0.01). No correlation was found between 25-hydroxyvitamin D levels and vitamin D intake, graft-versus-host disease, corticoid use or survival rates.
Low levels of 25-hydroxyvitamin D were detected even before hematopoietic stem cell transplantation and were significantly lower at 180 days after hematopoietic stem cell transplantation, thus recommending vitamin D supplementation for children and adolescents submitted to hematopoietic stem cell transplantation.
研究发现,维生素D水平未达最佳状态在所有年龄组中都极为普遍,流行病学研究表明维生素D缺乏与疾病易感性(如感染和癌症)及死亡率之间存在关联。对于成年移植患者,有人提出维生素D的免疫调节特性可能在移植物抗宿主病的预防和治疗中发挥重要作用。
本研究的目的是评估接受异基因造血干细胞移植的儿童和青少年的血清25-羟维生素D水平。
对66名年龄在4至20岁的患者在三个阶段评估血清25-羟维生素D水平:造血干细胞移植住院前以及造血干细胞移植后30天和180天。对照组由25名健康儿童组成。
在造血干细胞移植前阶段,患者的2,5-二羟基维生素D水平低于对照组(25.7±12.3 ng/mL对31.9±9.9 ng/mL;p值=0.01),且25-羟维生素D缺乏的患病率更高(32%对8%;p值=0.01)。造血干细胞移植后患病率显著增加(p值=0.01),移植后180天有一半患者存在维生素D缺乏。在此阶段,血清25-羟维生素D平均水平为20.9±10.9 ng/mL,与基线相比显著下降(p值=0.01)。未发现25-羟维生素D水平与维生素D摄入量、移植物抗宿主病、皮质类固醇使用或生存率之间存在相关性。
即使在造血干细胞移植前就检测到25-羟维生素D水平较低,且在造血干细胞移植后180天显著降低,因此建议对接受造血干细胞移植的儿童和青少年补充维生素D。